null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Sacituzumab Biosimilar (Anti-Trop2) Antibody (HDBS0023)

SKU HDBS0023
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein Trop2
Reactivity Human
Host Species Humanized
Isotype IgG1
€431
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Sacituzumab (Anti-Trop2) Biosimilar Antibody (HDBS0023)

The Anti-Trop2 Sacituzumab Govitecan Biosimilar Mab (HDBS0023) is a novel monoclonal antibody designed for research involving the Trop2 protein, a cell surface molecule overexpressed in various cancer types. This biosimilar antibody, developed through innovative technology, shows high specificity and affinity for Trop2, making it a promising tool for targeted cancer therapy.Trop2, also known as tumor-associated calcium signal transducer 2, plays a crucial role in promoting tumor growth, metastasis, and resistance to therapy. By targeting Trop2 with the Sacituzumab Govitecan biosimilar antibody, researchers can effectively inhibit Trop2-mediated signaling pathways, leading to tumor regression and improved therapeutic outcomes.The validation studies of this biosimilar monoclonal antibody have demonstrated its efficacy in various applications, including immunohistochemistry, flow cytometry, and in vivo tumor models.

Its ability to selectively target Trop2-positive tumor cells while sparing normal tissues makes it a promising candidate for precision medicine approaches in cancer treatment.Overall, the Anti-Trop2 Sacituzumab Govitecan Biosimilar Mab (HDBS0023) offers a cutting-edge solution for researchers seeking to investigate the role of Trop2 in cancer biology and develop novel therapeutic strategies targeting this molecule. Its potential impact in improving patient outcomes and advancing precision oncology makes it a valuable asset in the field of cancer research.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose